18.10.2020 • News

Arlanxeo Sells Olefins to Mitsubishi

Saudi Aramco subisidiary Arlanxeo Canada has agreed to sell its olefins business to Diamond Petrochemicals Canada, a subsidiary of Japan’s Mitsubishi Corp.

Arlanxeo said the business, which produces butadiene and raffinate at the Bio-Industrial Park Sarnia in Ontario, no longer fits with its strategic focus. The companies believe that the business will develop and grow in the future under Mitsubishi’s ownership.

The Arlanxeo butyl rubber unit at the site is reported to be excluded from the deal and will continue all current production activities.

The transaction is expected to close in the first half of 2021, subject to the usual conditions and regulatory approvals.

Mitsubishi said it expects to continue operations in Sarnia, taking over all existing employees.

Arlanxeo was previously a 50:50 joint venture between Aramco and German specialty chemicals company Lanxess. Aramco took full control of the venture in December 2018.

Author: Elaine Burridge, Freelance Journalist

Arlanxeo Canada is selling its olefins business to Diamond Petrochemicals...
Arlanxeo Canada is selling its olefins business to Diamond Petrochemicals Canada, a subsidiary of Japan’s Mitsubishi Corp. Arlanxeo said the business, which produces butadiene and raffinate at the Bio-Industrial Park Sarnia, Ontario no longer fits with its strategic focus. (c) Arlanxeo

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read